FDA Misses a PDUFA Date: How to Read the Delay

The Problem

You bought a biotech stock ahead of its PDUFA date. The date passes. No approval, no Complete Response Letter, no press release. The stock drifts lower while you stare at your brokerage app, unsure whether to hold, sell, or double down. This guide tells you what is actually happening when a PDUFA date passes with no news. In late September 2026, Novo Nordisk’s Mim8 (denecimig) is 43 business days past its July 29 PDUFA with zero FDA communication. It is the longest Q3 delay and a live case study in every signal described here.

The Solution

A PDUFA date is a goal date, not a deadline. The FDA can pass it without penalty, without public explanation, and without telling anyone when it will decide. When that happens, it is almost always one of three things: a pending Complete Response Letter, an undisclosed review-clock extension, or extended labeling negotiations. Here is how to tell which one you are dealing with.

Step-by-Step

Step 1: Understand what a PDUFA date actually is

PDUFA (Prescription Drug User Fee Act) is the law that lets the FDA collect application fees from drug companies. In exchange, the FDA commits to target review timelines: 10 months for standard review, 6 months for priority review from the date it accepts a New Drug Application (NDA) or Biologics License Application (BLA). The PDUFA date is the target action date set at acceptance. It is a goal, not a legally binding deadline. Congress reauthorizes PDUFA every five years (currently PDUFA VII). For the timeline details, see the FDA user fee programs page at fda.gov.

Step 2: Count business days, not calendar days

The FDA works on business days, and so should you. A PDUFA that falls on a Saturday or Sunday does not mean the drug was rejected. When counting how overdue an application is, exclude weekends and federal holidays.

Example: Novo Nordisk’s Mim8 PDUFA was July 29, 2026. As of September 3, the FDA has had 26 business days past that date. July 30, 31, August 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, September 1, 2, 3. That is nearly five weeks of working time. Most PDUFA overruns resolve within 5 to 10 business days. When you pass 20 business days with no communication, something structural is happening.

Step 3: Read the silence

A company that expects approval does not go silent. Approval press releases are drafted weeks in advance. When a PDUFA passes and the company says nothing, the silence itself is a signal. Here is what different silence patterns mean:

Complete silence (no press release, no 8-K, no FDA calendar update): This is the Mim8 scenario. Novo Nordisk has not issued a statement and the FDA calendar has not moved. Most likely: either an undisclosed review-clock extension (the FDA classified new information as a “major amendment” that resets the clock by three months), or extended labeling negotiations where both parties want a revised timeline before announcing anything. A pending CRL is possible but less likely. CRLs are formally issued and announced. The FDA does not sit on a CRL without issuing it.

Delayed but disclosed: In 2026, Savara reported that its MOLBREEVI PDUFA for autoimmune pulmonary alveolar proteinosis (aPAP) pushed from August 22 to November 22 after the FDA classified responses to information requests as a major amendment. The stock dropped roughly 13%. Capricor’s deramiocel for Duchenne muscular dystrophy also received a major-amendment extension to November 22. Both companies disclosed the delay. The transparency limits uncertainty, but a three-month clock reset is never good news.

The “FDA Approved: No” indicator: Drugs.com maintains an “FDA Approved: No” status on its New Drug Approvals page for drugs whose PDUFA date has passed without a decision. When that status flips to “Yes,” the drug was approved. When it stays at “No” for weeks past the date, check the company’s investor relations page for a statement. If neither source has updates, you are in the undisclosed-delay scenario.

Step 4: Know what a major amendment actually is

A major amendment is the FDA’s term for a substantial change to an application after it has been accepted for review. It can come from the sponsor (new data, a revised manufacturing plan, a new indication) or from the FDA (the agency asks for more information and decides the response is substantial enough to extend the clock). Either way, review extends by three months. Major amendments are administrative, not scientific. The FDA is not judging the drug’s efficacy. It is saying the application got more complex and needs more time.

An Advisory Committee (AdCom) does not extend the PDUFA date. AdCom votes are advisory and the FDA can still decide on the original date.

Step 5: Check these three sources yourself

When a PDUFA date passes with no news, here is exactly where to look:

Drugs.com (drugs.com/newdrugs.html): search the drug name. The “FDA Approved” field tells you whether a decision has been recorded. This is the fastest public source and updates before most news outlets.
Drugs@FDA (accessdata.fda.gov/scripts/cder/daf): the FDA’s own approval database. Approval letters, label text, and review documents are posted here, usually within a few days of the decision. If the drug appears under the original application number with an approval letter, it was approved. If nothing appears, the application is still pending.
Company investor relations page: every publicly traded biotech has an IR page with press releases and SEC filings. If the company has not posted a press release or filed an 8-K about the PDUFA outcome, the FDA has not issued a decision.

Check all three before acting. One blank source is normal. All three blank for more than five business days after the PDUFA is a delay signal.

Step 6: Size your position for the extended binary

A blown PDUFA date does not reduce binary risk. It stretches the same risk over more days. The three outcomes (approval, CRL, further extension) are still on the table, but with no date to anchor expectations. Implied volatility in the options market stays elevated and the stock typically drifts lower as date-specific holders exit.

The trading rule is simple: the position you had on PDUFA day was sized for the 37% CRL base rate. That number does not change because the date slipped. Do not add to a position after a delay unless you are willing to lose the full amount on a CRL. A disciplined investor sizes a PDUFA position at a level where a CRL (and the typical 30% to 60% single-day drop) does not blow up the portfolio. That math does not change just because the calendar did.

For a full breakdown of what happens after a CRL, see the CRL resubmission guide. For tracking every pending catalyst across the sector, see the Q3 2026 FDA calendar. And for the live worked example of a blown PDUFA in real time, follow the Mim8 delay coverage. When the decision finally does land - most drop after the close - the after-hours FDA decision guide tells you what to do with the print.

Common Mistakes

Assuming the FDA announces on the PDUFA date. About one in three applications receives a CRL (2018-2022 PDUFA cycle, per Avalere analysis of FDA user-fee data). For the other two-thirds, approvals often come 1 to 5 business days before the PDUFA date, rarely on it. A PDUFA date is the deadline for a decision, not the announcement date.

Adding to a position on the delay before the FDA acts. An unresolved PDUFA is the same binary on day 20 of the delay as on day 1. If the drug gets a CRL, you lose the same 30% to 60% whether you added shares at day 1 or day 20. Adding more capital to the same binary risk is not averaging down. It is increasing exposure to an unknown outcome.

Assuming the stock decline is pricing in a CRL. A stock that drifts from $48 to $45 over three weeks of delay is bleeding date-specific holders, not “pricing in” a rejection. Sentiment is not information. When the FDA acts, the stock will move on the outcome, not the drift. A CRL still drops it 30% to 60% from wherever it was trading.

Final Checklist

Count business days, not calendar days. Five business days overdue is very different from five calendar days.
Check Drugs.com for an “FDA Approved” status change.
Check the company IR page for a press release or 8-K filing.
If silent for more than 10 business days, look for a major-amendment extension announcement.
Do not add to the position. The binary risk is unchanged.
If holding through the delay, verify the position size was right for the 37% CRL base rate on day 1.